A clinical study of SYNB1020 in patients with hepatic-encephalopathy.
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2017
At a glance
- Drugs SYNB 1020 (Primary)
- Indications Hepatic encephalopathy
- Focus Adverse reactions
- 27 Jun 2017 New trial record
- 19 Jun 2017 According to a Synlogic media release, company plans to initiate this trial by mid-2018.